The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | NRG/RTOG 1112: sorafenib vs SBRT followed by sorafenib in HCC
Laura A. Dawson, MD, FASTRO, Princess Margaret Cancer Centre, Toronto, Canada, discusses the results of the NRG/RTOG 1112 randomized Phase III study (NCT01730937) of sorafenib vs. stereotactic body radiation therapy (SBRT) followed by sorafenib in hepatocellular carcinoma (HCC). Compared to sorafenib alone, SBRT improved overall survival & progression-free survival in patients with HCC, with no observed increase in adverse events, and a strong suggestion for quality of life benefit at 6 months. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
